Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asta Baranauskaite

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Pediatric Rheumatology Online Journal|July 29, 2025
The utility of miR-16, miR-146a and miR-155 in serum and urine for juvenile idiopathic arthritis diagnostics and monitoringAusra Snipaitiene, Kristina Snipaitiene, Andzelika Slegeryte, et al.
Annals of the Rheumatic Diseases|October 14, 2011
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND studyAsta Baranauskaite, Helena Raffayová, N V Kungurov, et al.
Arthritis Research & Therapy|December 21, 2024
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 studyNarendra Maharaj, Dharma Rao Uppada, Naveen Reddy, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 14, 2018
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study ResultsMichael E Weinblatt, Asta Baranauskaite, Eva Dokoupilova, et al.
Therapeutic Advances in Musculoskeletal Disease|October 28, 2021
Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trialDenis Poddubnyy, Effie Pournara, Agnieszka Zielińska, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 27, 2017
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid ArthritisMichael E Weinblatt, Asta Baranauskaite, Jaroslaw Niebrzydowski, et al.
Rheumatology (Oxford, England)|October 3, 2017
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritisPaul Emery, Jirí Vencovský, Anna Sylwestrzak, et al.
Annals of the Rheumatic Diseases|July 8, 2015
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapyPaul Emery, Jiří Vencovský, Anna Sylwestrzak, et al.
Rheumatology International|March 1, 2016
Musculoskeletal ultrasonography in routine rheumatology practice: data from Central and Eastern European countriesPeter Mandl, Asta Baranauskaite, Nemanja Damjanov, et al.
Arthritis Research & Therapy|April 4, 2016
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA studyDae Hyun Yoo, Artur Racewicz, Jan Brzezicki, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Pediatric Rheumatology Online Journal|July 29, 2025
The utility of miR-16, miR-146a and miR-155 in serum and urine for juvenile idiopathic arthritis diagnostics and monitoringAusra Snipaitiene, Kristina Snipaitiene, Andzelika Slegeryte, et al.
Annals of the Rheumatic Diseases|October 14, 2011
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND studyAsta Baranauskaite, Helena Raffayová, N V Kungurov, et al.
Arthritis Research & Therapy|December 21, 2024
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 studyNarendra Maharaj, Dharma Rao Uppada, Naveen Reddy, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 14, 2018
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study ResultsMichael E Weinblatt, Asta Baranauskaite, Eva Dokoupilova, et al.
Therapeutic Advances in Musculoskeletal Disease|October 28, 2021
Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trialDenis Poddubnyy, Effie Pournara, Agnieszka Zielińska, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 27, 2017
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid ArthritisMichael E Weinblatt, Asta Baranauskaite, Jaroslaw Niebrzydowski, et al.
Rheumatology (Oxford, England)|October 3, 2017
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritisPaul Emery, Jirí Vencovský, Anna Sylwestrzak, et al.
Annals of the Rheumatic Diseases|July 8, 2015
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapyPaul Emery, Jiří Vencovský, Anna Sylwestrzak, et al.
Rheumatology International|March 1, 2016
Musculoskeletal ultrasonography in routine rheumatology practice: data from Central and Eastern European countriesPeter Mandl, Asta Baranauskaite, Nemanja Damjanov, et al.
Arthritis Research & Therapy|April 4, 2016
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA studyDae Hyun Yoo, Artur Racewicz, Jan Brzezicki, et al.
Pageof 3